Post-Hoc Live
Post-Hoc Live
Podcast Description
Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.
Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]
Podcast Insights
Content Themes
The show covers critical themes in the biopharmaceutical industry including the implications of evolving AI technologies on drug development, vaccination policy and political influences on public health as exemplified by the discussions on the ACIP board, and sentiment analysis in biotechnology. Episodes have featured discussions on President Trump's drug pricing plans and the reaction of the pharma industry to significant political developments, such as his tariffs on pharmaceutical products.
Post-Hoc Live is an extension of Endpoints’ analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We’re bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.
Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]
It was a chaotic first year for this Trump administration’s FDA. The agency is down thousands of staff. Leadership was unstable. Industry insiders say they worry about the regulatory environment. What’s next? We’re joined by Holly Fernandez Lynch, an assistant professor of medical ethics at University of Pennsylvania's medical school and an FDA expert, to take stock of the past year at the FDA and look ahead to what we might see in year two.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.